No Data
WUXI APPTEC: Q1 net profit significantly increased, maintaining double-digit growth guidance for the year | Interpretations
① WUXI APPTEC's Q1 net income attributable to the parent company grew 89.1% year-on-year, mainly due to revenue growth, improved overall profitability, and the sale of WUXI XDC stocks; ② WUXI APPTEC still believes it can achieve its annual double-digit growth target.
WUXI APPTEC: Q1 revenue of 9.655 billion yuan, a year-on-year growth of 21%, with strong performance in the Business driving significant growth.
WUXI APPTEC's first quarter of 2025: strong performance growth driven by the chemical Business, TIDES Business revenue surged by 187%. Key financial highlights...
Summit Therapeutics Shares Are Trading Lower. The Company's Partner Akeso Received FDA Approval for Its PD-1 Monoclonal Antibody, Penpulimab-kcqx, in Combination With Cisplatin or Carboplatin and Gemcitabine. The FDA Also Approved Penpulimab-kcqx as a...
'Akeso Wins Chinese Approval For Cancer Drug Positioned To Rival Merck's Keytruda; Company Discloses Early Data Hinting At A Survival Benefit' - STAT News
Jiangsu Hengrui Pharmaceuticals: Authorized revenue becomes the "accelerator" for performance.
Personnel, products, and research and development are gradually becoming Global.
The upfront payment for the new ADC drug has boosted revenue, Jiangsu Hengrui Pharmaceuticals' Q1 revenue increased by 20.14% year-on-year, and net income increased by 36.9% | Earnings Reports insights.
In Q1, Jiangsu Hengrui Pharmaceuticals' revenue increased by 20.14% year-on-year, net income attributable to the parent company increased by 36.9%, and net income after deductions increased by 29.35% year-on-year. The significant increase in net income was primarily due to the company receiving a $75 million upfront payment for external licensing.
